Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Antimicrobial resistance: what is pharma doing?

This article was originally published in Scrip

Executive Summary

The UK recently saw the launch of a five-year antimicrobial resistance strategy, an initiative which will see it work with organizations across the globe to tackle a problem that almost everyone saw coming, but few have been able to do much about. While many initially expected the pharma industry to exploit the problem with innovative new antimicrobials, the reality has been that pharma companies have been forced to scale down their antimicrobial efforts or bow out of the area. Scrip spoke to Dr Catriona McMahon, AstraZeneca's director of UK medical and healthcare affairs, to find out why.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts